2023 CBIIC in Suzhou Industrial Park on September 25-27, 2023.
Member of PhIRDA Drug R&D Specialty Committee Director, Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College
Xiaoguang Chen, Director of Pharmacology Department of IMM, CAMS&PUMC, Deputy Director of the State Key Laboratory of Active Substances in Natural Medicines. She was elected as Millions of Talent Projects National candidates and awarded the State Council Special allowance. She has won the first prize of the first DEBIOPHARM-CCRF China Award. In 1996, 1997, and 2001, she worked as a visiting professor or visiting scholar in related universities and research institutions in Japan, Switzerland, and United States. Her major is in the research of cancer molecular pharmacology and new drug development. Her main research areas are new targets for anti-tumor drug research, signaling pathway inhibitors, and new drug research closely related to immunotherapy. She has published more than 150 academic papers, applied for more than 60 domestic and foreign patents, obtained 40 authorized patents, edited 3 postgraduate textbooks and developed several innovative medicines. As the head of the project, she has completed 5 patent transfers of Class 1.1 new drugs with a total package of nearly 500 million RMB. The new drug for small molecule cancer immunotherapy she has developed is at the leading position in china and abroad. She has made significant achievements in basic research and R&D of small molecule drugs.